Table 1.

Biomarkers used for Huntington’s Disease.

References	Biomarker(s) Type/Tool	Key Findings	Implication/Significance
[38,39]	White Matter (Imaging)	Emphasis on its significance; alterations seen over a decade before anticipated disease onset.	Crucial for understanding disease progression.
[40]	Imaging Data	Data amalgamated from 1082 participants over 1–10 years from various studies.	Indicates imaging as a viable endpoint in clinical trials due to heightened sensitivity.
[41,42]	mHTT (Wet Biomarker)	Correlates with clinical scores, CSF tau, and NfL.	mHTT potentially released from compromised neurons; possible biomarker for HD.
[43]	mHTT (Wet Biomarker)	Significant in HD pathogenesis.	Crucial gauge of pharmacodynamics for huntingtin-lowering therapies.
[44]	CSF mHTT (Wet Biomarker)	Derived from striatal cells.	Suggested as PD biomarker for therapeutic engagement evaluations.
[45]	[11C]CHDI-626 (PET)	Examined for mHTT PET imaging in zQ175DN mouse model.	Proves effective for mHTT PET imaging despite rapid metabolism.
[46]	mHTT and CBVa	Early HTT-lowering treatment defers onset and decelerates progression in mHTT mouse model; CBVa alteration influenced by mHTT on neural activity.	Indicates potential therapeutic interventions and understanding neuronal dysfunction mechanisms.